Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | RECQL | P46063 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9876643 | 0.69 | ALDH1A1 (0.33) | ALDH1A1HPGDMAPTRECQLKMT2A | |
| SCHEMBL11666449 | 0.67 | ALDH1A1 (0.32) | ALDH1A1HPGDMAPTRECQLKMT2A | |
| SCHEMBL7695989 | 0.63 | — | — | |
| SCHEMBL28188488 | 0.60 | DHFR (0.33) | KMT2AMEN1 | |
| SCHEMBL7065553 | 0.59 | MAPT (0.32) | ALDH1A1MAPTRECQLKMT2APOLB | |
| SCHEMBL7248147 | 0.58 | ALDH1A1 (0.47) | ALDH1A1HPGDKMT2AL3MBTL1MEN1 | |
| SCHEMBL1661599 | 0.57 | — | — | |
| SCHEMBL13085024 | 0.57 | NPSR1 (0.46) | ALDH1A1HPGDMAPTRECQLKMT2A | |
| SCHEMBL8755108 | 0.57 | L3MBTL1 (0.41) | ALDH1A1HPGDKMT2AKDM4EL3MBTL1 | |
| SCHEMBL8770615 | 0.57 | ALDH1A1 (0.40) | ALDH1A1HPGDMAPTRECQLKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2640727-B1 | ALANINYL MAYTANSINOL ANTIBODY CONJUGATES | GENENTECH INC (US) | 2015-05-13 | — | — | EP | disclosed |
| EP-2640727-A1 | ALANINYL MAYTANSINOL ANTIBODY CONJUGATES | Genentech, Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012074757-A1 | ALANINYL MAYTANSINOL ANTIBODY CONJUGATES | GENENTECH, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| US-20120121615-A1 | ALANINYL MAYTANSINOL ANTIBODY CONJUGATES | GENENTECH, INC. | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121615-A1 | ALANINYL MAYTANSINOL ANTIBODY CONJUGATES | MTX2, FOLH1, MGAT3 | ALDH1A1 238/4885HPGD 1752/4885MAPT 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.